Positive Interim Analysis of the FALCON Study
2024 Summary
Important events during 2024
KL1333
- In July, Abliva announced a positive outcome of the interim analysis of the 24-week data of the FALCON study with KL1333, increasing the probability of a positive readout upon completion of the full study.
Financial
- In February, the Board of Directors resolved on a capital raise totaling app. SEK 88 million through a fully guaranteed rights issue and a directed issue of convertible bonds.
- The new share issue with preferential rights for existing shareholders, announced in February and carried out in April, was subscribed to 100 percent. Abliva raised approximately SEK 46 million before deduction for transactions costs.
- Following the positive outcome of the interim analysis, Abliva was in August provided with additional proceeds of SEK 42 million before transaction costs through the conversion of the convertible bonds pledged in the capital raise in February.
Public cash offer from Pharming Techonologies B.V.
- As per 20 February 2025, Pharming Technologies B.V. controls in total 1,494,181,625 shares and votes in Abliva, corresponding to approximately 92.7 percent of the total number of shares and votes in Abliva.
- On 7 February 2025, Pharming declared unconditional, with approximately 87.7 percent of the total number of shares and votes in Abliva, and completed the recommended cash offer to the shareholders of Abliva and extended the acceptance period until February 20, 2025.
- Following an announcement of Pharming Technologies B.V. on December 15, 2024, on a public cash offer to acquire all shares in Abliva for SEK 0.45 per share, the Board of Directors of Abliva unanimously recommended the shareholders of Abliva to accept the offer. The acceptance period for the offer commenced on 16 January 2025.
Financial information
October-December 2024*
- Net revenues: SEK 0 (137,000)
- Other operating income: SEK 207,000 (0)
- Loss before tax: SEK 26,478,000 (25,258,000)
- Loss per share before dilution: SEK 0.02 (0.02)
- Diluted loss per share: SEK 0.02 (0.02)
January-December 2024*
- Net revenues: SEK 0 (137,000)
- Other operating income: SEK 497,000 (1,345,000)
- Loss before tax: SEK 89,954,000 (95,518,000)
- Loss per share before dilution: SEK 0.07 (0,09)
- Diluted loss per share: SEK 0.07 (0.09)
* APM Alternative performance measures, see definition on page 19.
The complete Interim report is available for download below and through Abliva's website www.abliva.com.
For more information, please contact:
Catharina Johansson, Deputy CEO, CFO & VP Investor Relations
+46 (0)46-275 62 21, ir@abliva.com
Abliva AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
info@abliva.com, www.abliva.com
Abliva - Delivering mitochondrial health
Abliva discovers and develops medicines for the treatment of mitochondrial disease. This rare and often very severe disease occurs when the cell's energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD? and NADH, has entered late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI). For more information, please visit?www.abliva.com.?Subscribe to our news and follow us on?LinkedIn?and YouTube.
